- Home
- OIA vs VNDA Comparison
OIA vs VNDA Comparison
Compare OIA & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OIA
- VNDA
- Stock Information
- Founded
- OIA 1988
- VNDA 2002
- Country
- OIA United States
- VNDA United States
- Employees
- OIA N/A
- VNDA N/A
- Industry
- OIA Finance Companies
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- OIA Finance
- VNDA Health Care
- Exchange
- OIA Nasdaq
- VNDA Nasdaq
- Market Cap
- OIA 287.4M
- VNDA 282.8M
- IPO Year
- OIA N/A
- VNDA 2006
- Fundamental
- Price
- OIA $5.99
- VNDA $4.98
- Analyst Decision
- OIA
- VNDA Strong Buy
- Analyst Count
- OIA 0
- VNDA 2
- Target Price
- OIA N/A
- VNDA $16.50
- AVG Volume (30 Days)
- OIA 97.9K
- VNDA 751.6K
- Earning Date
- OIA 01-01-0001
- VNDA 05-07-2025
- Dividend Yield
- OIA 4.88%
- VNDA N/A
- EPS Growth
- OIA N/A
- VNDA N/A
- EPS
- OIA N/A
- VNDA N/A
- Revenue
- OIA N/A
- VNDA $198,772,000.00
- Revenue This Year
- OIA N/A
- VNDA $14.36
- Revenue Next Year
- OIA N/A
- VNDA $44.53
- P/E Ratio
- OIA N/A
- VNDA N/A
- Revenue Growth
- OIA N/A
- VNDA 3.18
- 52 Week Low
- OIA $4.93
- VNDA $3.71
- 52 Week High
- OIA $6.72
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- OIA 35.74
- VNDA 58.23
- Support Level
- OIA $6.04
- VNDA $4.84
- Resistance Level
- OIA $6.17
- VNDA $5.10
- Average True Range (ATR)
- OIA 0.06
- VNDA 0.24
- MACD
- OIA -0.02
- VNDA 0.02
- Stochastic Oscillator
- OIA 4.00
- VNDA 76.40
About OIA Invesco Municipal Income Opportunities Trust
Invesco Muni Income Opps Trust operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income which is exempt from federal income tax.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.